PT-141 acts on melanocortin receptors in the brain — the system responsible for desire in both men and women. Provider-prescribed after review. Addresses arousal at the neurological level, not the vascular one.
Individual results vary and are not guaranteed. Provider approval required before any prescription is issued. Results depend on individual clinical profile.
PT-141 (bremelanotide) is a cyclic peptide that activates melanocortin receptors — specifically MC3R and MC4R — in the central nervous system. This is a fundamentally different mechanism than PDE5 inhibitors like Viagra or Cialis, which work downstream on vascular smooth muscle to enhance blood flow.
PT-141 works upstream. It acts on the neurological pathways in the brain that generate desire and arousal — not on the vascular response that follows. The distinction matters: vascular treatments address the physical response to arousal but don't address the desire itself. PT-141 addresses the source.
It's the only peptide of its class clinically studied in both men and women for sexual dysfunction. Compounded subcutaneously and used on-demand — 45 to 60 minutes before intended activity. Prescribed after provider review. Compounded by a licensed 503B pharmacy. Delivered monthly.
Not vascular.
Not hormonal.
Neurological — at the receptor level.
Prescribed by a licensed physician.
Compounded by a 503B pharmacy.
Dosed on-demand — no daily commitment.
Studied in both men and women — the only peptide of its class to address desire at the brain level rather than the body's response to it.
PT-141 is prescribed as a single compounded formulation. Your provider determines candidacy and dosing based on your intake and clinical history.
Compounded by a licensed 503B outsourcing facility. Not an FDA-approved finished drug product. Provider approval required. Results vary.
PT-141 works on the brain's arousal pathway — specifically the melanocortin system — not on vascular response. This means it addresses desire at the neurological level, not just the physical. For patients who've found vascular treatments insufficient or irrelevant to their experience, this distinction is clinically significant.
Most sexual health pharmacology has been developed for male vascular response. PT-141 is distinct — it has been studied in both men and women for hypoactive sexual desire disorder (HSDD) and related conditions. The melanocortin pathway operates similarly across sexes, making this one of the few compounds applicable to both with clinical data supporting each.
PT-141 is dosed as needed — 45 to 60 minutes before intended activity — rather than taken daily. There is no accumulation requirement and no lifestyle adjustment to accommodate a medication schedule. If approved, your provider will prescribe an appropriate dose and injection volume based on your clinical profile.
PT-141 does not affect testosterone, estrogen, or any component of the endocrine system. It is a peptide, not a hormone or hormone analog. Patients concerned about hormonal balance — including those already on hormone optimization protocols — can discuss compatibility directly with their provider. No known interaction with HRT or TRT has been identified at therapeutic doses.
Hormonal shifts from pregnancy, postpartum changes, perimenopause, or chronic stress can significantly alter libido. Conventional medicine often has no pharmacological answer. PT-141 targets the melanocortin system — the neurological substrate of desire — rather than estrogen or hormone levels. If approved by your provider, it offers a mechanism that addresses the source rather than the symptom.
PDE5 inhibitors (Viagra, Cialis) are effective for vascular erectile response but do not address desire or arousal directly. Men who find that desire has changed, or for whom vascular treatments are contraindicated or insufficient, may benefit from PT-141's central mechanism. Provider evaluation determines candidacy based on your specific clinical profile.
This is not a supplement or a lifestyle product. PT-141 is a clinician-prescribed peptide with a specific mechanism of action. Adults who understand the distinction between a neurological and a vascular approach — and want a provider-guided protocol with a 503B-compounded compound — are the intended patient profile.
Your intake screens for all contraindications. Every candidate is reviewed by a licensed physician before any prescription is issued. If you're borderline on any criteria, your provider will advise you directly — no guesswork, no charge if not approved.
A structured medical questionnaire covering health history, current medications, cardiovascular background, and contraindication screening. Under five minutes. No video call required. Completed entirely on your schedule — discreetly.
A board-certified physician reviews your intake within 48 hours. They evaluate candidacy, review cardiovascular and medication contraindications, and issue your prescription if approved. If not approved, you are notified with clinical reasoning — no charge.
Your compounded PT-141 ships from a licensed 503B outsourcing facility — discreet packaging, tracked delivery, direct to your door. No pharmacy visit. No insurance required. Monthly supply included with your subscription.
Administer subcutaneously 45 to 60 minutes before intended activity. Your provider will specify your dose. Direct messaging access to your care team is included — questions, adjustments, and follow-up are managed remotely on your schedule.
After my second pregnancy, I thought my libido had just… changed permanently. My OB-GYN had no real answers. PT-141 was the first thing that actually addressed the neurological side of it — not just "try to relax." I wasn't expecting something to actually work at that level. It did.
I wasn't looking for Viagra. I was looking for something that worked at a different level — something that addressed what was actually changing, which wasn't vascular. PT-141 is that. The difference is night and day from anything I'd tried before. The mechanism is simply more relevant to what I was experiencing.
I was skeptical that something this affordable would actually deliver. I've been wrong before, but not often about something this personal. The on-demand dosing made it easy to integrate. My provider was thorough and straightforward. Worth starting sooner than I did.
Individual results vary and are not typical. Testimonials reflect patient-reported experiences and are used as illustrations only. Results are not guaranteed. All patients are under licensed physician supervision. If approved for treatment.
Subscriptions renew monthly. Cancel anytime before your renewal date — no fees, no calls required. Provider review is required before any prescription is issued. All treatments require physician approval. Results vary. FSA/HSA eligibility depends on your individual plan.
The mechanism is fundamentally different. Viagra and Cialis are PDE5 inhibitors — they work by relaxing vascular smooth muscle to increase blood flow to genital tissue. They enhance the physical response to arousal but don't act on desire or arousal itself. PT-141 (bremelanotide) is a melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system — the neurological pathways responsible for generating desire and arousal. It operates upstream of vascular response, addressing the brain's arousal signaling rather than the body's downstream reaction. For patients who've found vascular treatments insufficient or irrelevant to their experience, this distinction is clinically significant. The two classes are not equivalent and are not interchangeable.
Yes — and this is one of PT-141's most clinically significant characteristics. Most sexual health pharmacology has been developed for male physiology and vascular response. PT-141 is one of the few compounds that has been studied in women for hypoactive sexual desire disorder (HSDD) and related conditions. The melanocortin receptor system involved — MC3R and MC4R — operates similarly in both sexes, which is why the mechanism is applicable across genders. Bremelanotide is actually the active moiety of Vyleesi, which received FDA approval for HSDD in premenopausal women (for a branded formulation at a different dosage). The compounded version prescribed through AnthologyRX is not FDA-approved as a finished drug product but is compounded under 503B standards and prescribed by a licensed physician after clinical evaluation. Provider review determines individual candidacy.
PT-141 is administered as a subcutaneous injection — typically into the abdomen or outer thigh — approximately 45 to 60 minutes before intended activity. It is dosed on-demand, not daily. Your provider will specify your dose and injection volume based on your clinical profile. Injection supplies (syringes and alcohol pads) are included with your monthly shipment. If you have no experience with self-injection, your care team provides written guidance and is available for follow-up via direct message. The injection itself is simple and routinely performed by patients without any clinical background after brief instruction.
The most commonly reported side effects are nausea, flushing, and transient increases in blood pressure — particularly in the first hour after dosing. These are typically mild and resolve within a few hours. Nausea is the most frequent complaint and tends to decrease with subsequent doses as tolerance develops. Because PT-141 can cause blood pressure elevation, it is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, or relevant cardiac history — your intake screens for these specifically. Facial flushing is common and generally self-limiting. Injection-site reactions (mild redness, irritation) may occur. Your provider will review your full risk profile before prescribing. If approved, you'll be counseled on what to monitor and when to contact your care team.
Your provider reviews your full medication list as part of the intake process. PT-141 is generally not combined with PDE5 inhibitors (Viagra, Cialis, Levitra) without careful provider evaluation, as the combination may produce additive effects on blood pressure. Antihypertensives, certain antidepressants, and medications affecting blood pressure should be disclosed during intake. PT-141 is non-hormonal and does not interact with testosterone, estrogen, or most hormone-based treatments at the pharmacokinetic level — however, your provider evaluates your complete clinical picture before prescribing. If you are on an AnthologyRX hormone optimization or other protocol, disclose this during intake. Do not use PT-141 with alcohol in large quantities, as this may increase the risk of adverse blood pressure effects.
Prescription medications — including compounded peptides prescribed by a licensed physician for a diagnosed medical condition — are generally eligible for FSA and HSA reimbursement. AnthologyRX issues an itemized receipt automatically with each subscription cycle that includes the prescribing physician's information and the medication details, formatted for FSA/HSA submission. However, eligibility ultimately depends on your specific plan administrator's determination. Some FSA/HSA plans require a letter of medical necessity from your provider — your care team can provide this documentation upon request. We recommend confirming eligibility directly with your plan administrator if you are uncertain.
Your intake takes five minutes. Provider review within 48 hours. No clinic visit. No waiting room. No guesswork.
